Good day, everyone, and welcome to Pfizer Pflash, a spotlight on the PD-1 VEGF bispecific PF-4404 clinical development strategy. Today's call is being recorded. At this time, I would like to turn the ...

Q4 2025 Management View Peter Greenleaf, President, CEO & Director, opened the call announcing "strong LUPKYNIS sales in 2025 ...

SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports that an analyst research report was published on the Company that explains ...

Vantage Clinical Partners provides assessment, program development, and operational optimization services across key ...

Jupiter’s strategy combines clinical development with active commercial revenue generation. The Company views direct engagement with the investment community as an ongoing part of its philosophy to ...

Company reports encouraging monotherapy expansion data in platinum-resistant ovarian cancer and initiates first combination study with standard-of-care chemotherapies in Q1 2026 Timothy Bowler, M.D., ...

As clinical development grows more complex, sponsors are rethinking how outsourcing models, technology, and partnerships align to support both speed and sustainability. The shift toward hybrid models, ...

SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that an analyst research report was published on the Company that explains ...